First identification of the SARS-COV-2/XBB.1.5 sublineage among indigenous COVID-19 cases through the influenza sentinel surveillance system in Niger
Adamou Lagaré,
No information about this author
Martin Faye,
No information about this author
Moussa Issa
No information about this author
et al.
Heliyon,
Journal Year:
2023,
Volume and Issue:
9(11), P. e20916 - e20916
Published: Oct. 19, 2023
The
emergence
of
the
Omicron
variant
in
November
2021,
has
caused
panic
worldwide
due
to
rapid
evolution
and
ability
virus
escape
immune
system.
Since,
several
sublineages
(BA.1
BA.5)
their
descendent
recombinant
lineages
have
been
circulating
worldwide.
Furthermore,
December
2022,
a
new
subvariant
XBB.1.5
characterized
by
an
unusual
mutation
spike
protein
evolved
United
States
rapidly
spread
other
continents.
Our
study
reports
on
first
cases
sublineage
among
indigenous
Severe
Acute
Respiratory
Syndrome
Coronavirus-2
(SARS-COV-2)
positive
detected
through
influenza
sentinel
surveillance
system
Niger.
All
suspected
were
tested
for
both
SARS-COV-2
using
Centre
Disease
Control
prevention
(CDC)
Influenza
Multiplex
quantitative
Reverse-Transcription
Polymerase
Chain
Reaction
(qRT-PCR)
Assay.
samples
with
cycle
threshold
≤28
selected
whole
genome
sequencing
subsequently
Oxford
Nanopore
Midnight
protocol
barcoding
MinIon
MK1B
device.
A
total
51
confirmed
between
2022
March
2023.
We
successfully
obtained
19
sequences
predominance
XBB.1/XBB.1.5
(73.7
%).
In
addition,
XBD
sequence
was
also
first-ever
identified
early
findings
support
need
strengthen
routine
Coronavirus
2019
(COVID-19)
variants
monitoring
Language: Английский
SARS-CoV-2 Genotyping Highlights the Challenges in Spike Protein Drift Independent of Other Essential Proteins
Jeremy W. Prokop,
No information about this author
Sheryl Alberta,
No information about this author
Martin Witteveen‐Lane
No information about this author
et al.
Microorganisms,
Journal Year:
2024,
Volume and Issue:
12(9), P. 1863 - 1863
Published: Sept. 9, 2024
As
of
2024,
SARS-CoV-2
continues
to
propagate
and
drift
as
an
endemic
virus,
impacting
healthcare
for
years.
The
largest
sequencing
initiative
any
species
was
initiated
combat
the
tracking
changes
over
time
at
a
full
virus
base-pair
resolution.
represents
unique
opportunity
understand
selective
pressures
viral
evolution
but
requires
cross-disciplinary
approaches
from
epidemiology
functional
protein
biology.
Within
this
work,
we
integrate
two-year
genotyping
window
with
structural
biology
explore
on
insights.
Although
genotype
Spike
(Surface
Glycoprotein)
continue
drift,
most
proteins
have
had
few
amino
acid
alterations.
Spike,
high
rate
acids
involved
in
antibody
evasion
also
corresponds
within
ACE2
binding
pocket
that
undergone
multiple
maintain
binding.
suggests
pressure
receptor
specificity
could
confer
risk.
Mapping
structures
co-transcriptional
complex
(nsp7-nsp14),
nsp3
(papain-like
protease),
nsp5
(cysteine
protease)
suggest
they
remain
critical
factors
drug
development
will
be
sustainable,
unlike
those
strategies
targeting
Spike.
Language: Английский
Tiled Amplicon Sequencing Enables Culture-free Whole-Genome Sequencing of Pathogenic Bacteria From Clinical Specimens
bioRxiv (Cold Spring Harbor Laboratory),
Journal Year:
2024,
Volume and Issue:
unknown
Published: Dec. 20, 2024
Abstract
Pathogen
sequencing
is
an
important
tool
for
disease
surveillance
and
demonstrated
its
high
value
during
the
COVID-19
pandemic.
Viral
pandemic
allowed
us
to
track
spread,
quickly
identify
new
variants,
guide
development
of
vaccines.
Tiled
amplicon
sequencing,
in
which
a
panel
primers
used
multiplex
amplification
fragments
across
entire
genome,
was
cornerstone
SARS-CoV-2
sequencing.
The
speed,
reliability,
cost-effectiveness
this
method
led
implementation
academic
public
health
laboratories
world
adaptation
broad
range
viral
pathogens.
However,
similar
methods
are
not
available
larger
bacterial
genomes,
whole-genome
typically
requires
vitro
culture.
This
increases
costs,
error
rates
turnaround
times.
need
culture
poses
particular
problems
medically
bacteria
such
as
Mycobacterium
tuberculosis,
slow
grow
challenging
As
proof
concept,
we
developed
two
novel
panels
M.
tuberculosis
Streptococcus
pneumoniae
.
Applying
our
clinical
samples,
show
ability
classify
pathogen
subgroups
reliably
markers
drug
resistance
without
culturing.
Development
work
settings
has
potential
dramatically
reduce
time
diagnosis
multiple
drugs
parallel,
enabling
earlier
intervention
priority
Language: Английский